NASDAQ:CBST Cubist Pharmaceuticals (CBST) Stock Price, News & Analysis → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free CBST Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Cubist Pharmaceuticals alerts: Email Address Ad Banyan Hill PublishingTrump’s Former Wingman Bets Big on AIOne of his AI company’s earliest investors was the CIA’s venture capital arm called In-Q-Tel … named after Q, the fictional character who makes gadgets for James Bond. Soon, an alphabet soup of 30 government agencies would entrust the company with their most sensitive information.Get the full story here. About Cubist Pharmaceuticals Stock (NASDAQ:CBST)Cubist Pharmaceuticals, Inc. (Cubist) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings. As of December 31, 2011, the Company had two marketed products, CUBICIN (daptomycin for injection) and ENTEREG (alvimopan). The Company also co-promotes DIFICIDTM in the United States, under its co-promotion agreement with Optimer Pharmaceuticals, Inc. (Optimer). In September 2013, the Company announced that it has completed the acquisition of Trius Therapeutics Inc. In October 2013, the Company announced that it has completed its acquisition of Optimer Pharmaceuticals, Inc.Read More Ad Banyan Hill PublishingTrump’s Former Wingman Bets Big on AIOne of his AI company’s earliest investors was the CIA’s venture capital arm called In-Q-Tel … named after Q, the fictional character who makes gadgets for James Bond. Soon, an alphabet soup of 30 government agencies would entrust the company with their most sensitive information.Get the full story here. CBST Stock News HeadlinesApril 11, 2024 | bbc.co.ukKey facts about CubismJanuary 13, 2024 | seekingalpha.comCBST:CA The Cannabist Company Holdings Inc.May 16, 2023 | bbc.co.ukWhat is Cubism?April 7, 2023 | thestreet.comCubist Stock Hits New 52-Week High (CBST)March 30, 2023 | thestreet.comCubist Rises On Unusually High Volume (CBST)March 18, 2023 | thestreet.comTetraphase Antibiotic Nearing Key Tolerability TestMarch 11, 2023 | benzinga.comCubist Raises $7M to Make dApp Development More Efficient, Secure, and ScalableMarch 4, 2023 | thestreet.comTetraphase: Another Good Investment In Hot Antibiotic MarketDecember 17, 2022 | thestreet.comCubist Pharmaceuticals (CBST) Stock Skyrockets Today on $8.4 Billion Merck DealSee More Headlines Receive CBST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cubist Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/21/2014Today5/14/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryBiotechnology Current SymbolNASDAQ:CBST CUSIP22967810 CIK912183 Webwww.cubist.com Phone+1-781-8608660FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report CBST Stock Analysis - Frequently Asked Questions How were Cubist Pharmaceuticals' earnings last quarter? Cubist Pharmaceuticals Inc (NASDAQ:CBST) released its quarterly earnings results on Tuesday, October, 21st. The biopharmaceutical company reported $0.58 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.54. The biopharmaceutical company had revenue of $309.20 million for the quarter, compared to analysts' expectations of $305.50 million. The business's quarterly revenue was up 16.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.41 EPS. What other stocks do shareholders of Cubist Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cubist Pharmaceuticals investors own include Intercept Pharmaceuticals (ICPT), Ionis Pharmaceuticals (IONS), Netflix (NFLX), Novavax (NVAX), (QIHU) (QIHU), Seagen (SGEN), Bausch Health Companies (BHC), Baidu (BIDU), Booking (BKNG) and BioMarin Pharmaceutical (BMRN). This page (NASDAQ:CBST) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Crypto 9-5 Escape PlanCrypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmithBuy this small stock before coming AI Tidal WaveChaikin AnalyticsCharles Payne Demystifies OptionsUnstoppable ProsperityRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap Sniper Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cubist Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
